Loading…
Develops AAV gene therapies for rare, monogenic central nervous system diseases in children.
Develops AAV gene therapies for rare, monogenic central nervous system diseases in children.
Has no product on sale, so it funds trials with money raised from investors, and revenue would start only with an approval or a licensing deal. A gene therapy is meant to be a one-time treatment, which is why such drugs are priced per patient rather than as a recurring prescription.
Moat: none (IP / patents). Addresses ultra-rare pediatric CNS diseases with no approved treatments, but is clinical-stage and cash-constrained.
Headquarters: Dallas, Texas, US · Founded: 2018 · Employees: 99
Size Taysha Gene Therapies (TSHA) is a United States Health Care company (Biotechnology) with a market value of $1.41B, the 2038th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.33 on 6 Nov 2026.
Performance Over six months the shares fell 36.4%, against -19.4% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 18 in its peer set.
Growth Revenue fell 32.3% over the last twelve months (peer median +18.4%); the operating margin is -2,854.9% (peer median -7.4%).
Valuation It trades at 184.6× enterprise value to sales against a peer median of 8.7× (5th most expensive of 15).
Short interest Short interest is 15.7% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $5.49M | $9.77M | $8.33M | $15.5M | $2.50M |
| Revenue growth | — | +17% | -46% | +518% | — |
| Gross profit | $4.31M | $8.63M | $7.09M | $14.1M | $15,000 |
| EBITDA | -$155M | -$109M | -$85.4M | -$70.0M | -$124M |
| Net income | -$150M | -$109M | -$89.3M | -$112M | -$166M |
| Free cash flow | -$133M | -$93.8M | -$81.6M | -$76.9M | -$109M |
| Capital expenditure | $3.38M | $738,000 | $374,000 | $7.37M | $24.9M |
| Total debt | $56.9M | $70.5M | $64.0M | $61.1M | $59.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies TSHA | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a |
| PTC Therapeutics PTCT | $5.47B | -11% | -35% | 22% | 3.4× | 8.0% |
| Sarepta Therapeutics SRPT | $1.88B | -11% | -20% | -3% | 1.1× | 11.9% |
| uniQure QURE | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TSHA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.3% | -2.7% | 11th highest of 21 |
| 6-month return | -36.4% | -19.4% | 5th lowest of 18 |
| Distance from 52-week high | -40.7% | -41.7% | 10th highest of 21 |
| Revenue growth (TTM) | -32.3% | +18.4% | 2nd lowest of 17 |
| Operating margin | -2,854.9% | -7.4% | lowest of 16 |
| EV / Sales | 184.6× | 8.7× | 5th most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |